|
| |
Biopartners terminates collaboration with The Medical House
Baar, Switzerland 17 December 2007:
Biopartners Holdings AG today
announced that it has terminated its supply agreement with The Medical House. In
February 2005, The Medical House signed a 10 year supply agreement with
Biopartners GmbH for the license and supply
of The Medical House’s GH1 reusable, spring powered, needle-free delivery system
for the delivery of Biopartners’
human growth hormone product, Valtropin®.
In 2006 Biopartners initiated a
comparative bioavailability/bioequivalence study in volunteers to assess
Valtropin delivered by The Medical House’s
GH1. The Medical House has never been able to supply
Biopartners with the GH1 devices needed to perform this
clinical study. Therefore, Biopartners
terminated the collaboration.
“Having received EMEA approval in April 2006, we had planned to launch Valtropin
at the end of that year” commented Mr Jean-Noël Treilles, CEO of Biopartners.
“However, with the
GH1 device not functioning correctly, we have had to end our agreement with The
Medical House in order to seek a suitable and robust alternative delivery
system.”
For further information on Biopartners please contact:
Marie-Joëlle Gaufrès, Head of Commercial Operations
marie-joelle@Biopartners.ch
Phone: +41 (0)41 766 20 80
About Biopartners Holdings AG
Headquartered in Baar, Switzerland, with an affiliate in Germany,
Biopartners is a global biopharmaceuticals company and a leader in the emerging
field of multi-source biopharmaceuticals. Biopartners’ mission is to develop
biopharmaceuticals and innovative formulations of “first generation”
biopharmaceuticals as well as advanced delivery systems that may improve patient
compliance. Biopartners is developing a comprehensive range of biopharmaceutical
products that may offer life-saving therapeutic benefits across many therapeutic
areas. Biopartners has submitted three dossiers to the EMEA and has a fourth
product in phase III on the way. In March 2007, Biopartners was acquired by a
Polish biotechnology company, Bioton S.A.
| |
|
